Literature DB >> 8327510

Resistance of human squamous carcinoma cells to transforming growth factor beta 1 is a recessive trait.

M Reiss1, T Muñoz-Antonia, J M Cowan, P C Wilkins, Z L Zhou, V F Vellucci.   

Abstract

Because most human squamous carcinoma cell lines of the aerodigestive and genital tracts are refractory to the antiproliferative action of transforming growth factor beta 1 (TGF beta 1) in vitro, we have begun to identify the causes for resistance of squamous carcinoma cell lines to TGF beta 1 by using somatic cell genetics. Two stable hybrid cell lines (FaDu-HKc.1 and FaDu-HKc.2) were obtained by fusing a TGF beta 1-resistant human squamous carcinoma cell line, FaDu-HygR, with a human papilloma virus 16-immortalized, TGF beta 1-sensitive, human foreskin keratinocyte cell line, HKc-neoR. Whereas TGF beta 1 did not inhibit DNA synthesis in parental FaDu-HygR cells, it reduced DNA synthetic activity of HKc-neoR, FaDu-HKc.1, and FaDu-HKc.2 cells by 75-85% (IC50, 2-5 pM). Although squamous carcinoma cells express lower than normal levels of TGF beta 1 type II receptors on their cell surface, TGF beta 1 type II receptor mRNA was detected in all four cell lines. Recessive genes involved in TGF beta 1 signaling may be localized to the distal portion of chromosome 18q, as this was the sole chromosomal region of homozygous deletion in parental FaDu-HygR cells. Furthermore, our previous observation that mutant p53 decreases sensitivity of keratinocytes to TGF beta 1 was supported by the finding that the level of the mutant p53 protein expressed by the hybrid cell lines was greatly reduced. In summary, TGF beta 1 resistance of FaDu cells appears to be recessive and is presumably due to the loss of one or more post-receptor elements of the signaling pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8327510      PMCID: PMC46912          DOI: 10.1073/pnas.90.13.6280

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Growth modulation of mouse keratinocytes by transforming growth factors.

Authors:  R J Coffey; N J Sipes; C C Bascom; R Graves-Deal; C Y Pennington; B E Weissman; H L Moses
Journal:  Cancer Res       Date:  1988-03-15       Impact factor: 12.701

2.  Regulation of growth and differentiation of human keratinocytes by type beta transforming growth factor and epidermal growth factor.

Authors:  M Reiss; A C Sartorelli
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

3.  Modulation of the mitogenic response of an epidermal growth factor-dependent keratinocyte cell line by dexamethasone, insulin, and transforming growth factor-beta.

Authors:  J G Zendegui; W H Inman; G Carpenter
Journal:  J Cell Physiol       Date:  1988-08       Impact factor: 6.384

4.  mRNA phenotyping by enzymatic amplification of randomly primed cDNA.

Authors:  K E Noonan; I B Roninson
Journal:  Nucleic Acids Res       Date:  1988-11-11       Impact factor: 16.971

5.  Induction and autocrine receptor binding of transforming growth factor-beta 2 during terminal differentiation of primary mouse keratinocytes.

Authors:  A B Glick; D Danielpour; D Morgan; M B Sporn; S H Yuspa
Journal:  Mol Endocrinol       Date:  1990-01

6.  Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes.

Authors:  M Reiss; V F Vellucci; Z L Zhou
Journal:  Cancer Res       Date:  1993-02-15       Impact factor: 12.701

7.  Identification of a chromosome 18q gene that is altered in colorectal cancers.

Authors:  E R Fearon; K R Cho; J M Nigro; S E Kern; J W Simons; J M Ruppert; S R Hamilton; A C Preisinger; G Thomas; K W Kinzler
Journal:  Science       Date:  1990-01-05       Impact factor: 47.728

8.  Continuous cell lines with altered growth and differentiation properties originate after transfection of human keratinocytes with human papillomavirus type 16 DNA.

Authors:  L Pirisi; K E Creek; J Doniger; J A DiPaolo
Journal:  Carcinogenesis       Date:  1988-09       Impact factor: 4.944

9.  Reinitiation of DNA synthesis in quiescent mouse keratinocytes; regulation by polypeptide hormones, cholera toxin, dexamethasone, and retinoic acid.

Authors:  M Reiss; C L Dibble
Journal:  In Vitro Cell Dev Biol       Date:  1988-06

Review 10.  Transforming growth factor-beta: possible roles in carcinogenesis.

Authors:  A B Roberts; N L Thompson; U Heine; C Flanders; M B Sporn
Journal:  Br J Cancer       Date:  1988-06       Impact factor: 7.640

View more
  7 in total

1.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

2.  Interferon regulatory factor 7 mediates activation of Tap-2 by Epstein-Barr virus latent membrane protein 1.

Authors:  L Zhang; J S Pagano
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

Review 3.  Transforming growth factor-beta and prostate cancer.

Authors:  M S Steiner
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

4.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

5.  Attenuated transforming growth factor beta signaling promotes nuclear factor-kappaB activation in head and neck cancer.

Authors:  Jonah Cohen; Zhong Chen; Shi-Long Lu; Xin Ping Yang; Pattatheyil Arun; Reza Ehsanian; Matthew S Brown; Hai Lu; Bin Yan; Oumou Diallo; Xiao-Jing Wang; Carter Van Waes
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

6.  Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic.

Authors:  M W Lingen; P J Polverini; N P Bouck
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

7.  SMAD4 is a predictive marker for 5-fluorouracil-based chemotherapy in patients with colorectal cancer.

Authors:  J L Boulay; G Mild; A Lowy; J Reuter; M Lagrange; L Terracciano; U Laffer; R Herrmann; C Rochlitz
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.